Pfizer Takes J&J To Court As Analysts Shake Up Pharma Ratings
September 20, 2017 at 12:05 PM EDT
Morgan Stanley analyst David Risinger upgraded Pfizer this morning to Overweight, a Buy-equivalent rating, as he believes investors underappreciate the global prospects for breast cancer drug Ibrance.